The integration of CTLA-4 blockade into treatment (e.g., ipilimumab added to nivolumab, or tremelimumab added to PD-L1 therapy) has not eroded patient-reported well-being in trials—a testament to the adaptability of patients and clinicians in managing adverse effects, and to the benefit of achieving tumor regression that can alleviate cancer-related symptoms. This evidence concerns the gene CD274 and cancer.